Key result
Direct oral anticoagulants showed no significant difference in stroke, systemic embolism, or major bleeding across different body mass index classes in adults with atrial fibrillation.
Why the study?
Recent systematic reviews examining direct oral anticoagulants in obese adults with AF showed conflicting results and conclusions despite similar included studies.
Does DOAC therapy improve or maintain efficacy and safety outcomes in obese adults with atrial fibrillation compared to normal weight adults?
Comparison
Different BMI groups and different types of DOACs
Design
Systematic review of systematic reviews and meta-analysis
Follow-up
12 months and entire trial duration
Authors
Loading...
Supports consistent DOAC efficacy/safety across BMI in AF; leaves open questions for class III obesity.
Meta-Analysis
Does DOAC therapy improve or maintain efficacy and safety outcomes in obese adults with atrial fibrillation compared to normal weight adults?
DOACs appear to have similar efficacy and safety across different BMI classes in patients with atrial fibrillation, though data for class III obesity remains limited.
Shaikh et al. (2021) conducted a meta-analysis in Atrial Fibrillation in Obese Adults. Direct oral anticoagulants (DOACs) vs. Different BMI groups (Normal weight vs Overweight/Obese) was evaluated on Stroke (ischemic or hemorrhagic) or systemic or pulmonary embolism. Direct oral anticoagulants showed no significant difference in stroke, systemic embolism, or major bleeding across different body mass index classes in adults with atrial fibrillation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: